ACSF2

Across TCGA pan-cancer cohorts, ACSF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACSF2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACSF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACSF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ACSF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.381	0.870	.003	37	view →
CCRCC	OS	Tertile	All	1.000	0.856	.004	25	view →
HNSC	DFS	Median	All	0.919	0.985	.045	4	view →
LSCC	OS	Quartile	All	0.700	0.953	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACSF2–PDAC (DFS)

Open the PDAC breakdown →